A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis

Inclusion Criteria:

- Adult subjects with clinical diagnosis of chronic plaque psoriasis (with a disease
duration of at least 6 months) and at least 1 fingernail with nail psoriasis.

- Subject must have BSA ≥ 10% and a target fingernail mNAPSI ≥ 8 at Week 0, OR BSA ≥
5%, a target fingernail mNAPSI ≥ 8 and a total mNAPSI score of ≥ 20 at Week 0.

- Subject must have a Nail Psoriasis Physical Functioning Severity score of > 3, OR a
Nail Psoriasis Pain NRS score of >3.

- Subjects must have a Physician's Global Assessment (PGA) of Fingernail Psoriasis and
a PGA of Skin Psoriasis of at least moderate.

- Subject must have discontinued use of all systemic therapies for the treatment of
psoriasis, or systemic therapies known to improve psoriasis for at least 4 weeks
prior to Week 0, ustekinumab must have been discontinued at least 12 weeks prior to
Week 0.

- Target fingernail must have mNAPSI score of ≥ 8.

- Adult subjects with clinical diagnosis of chronic.

Exclusion Criteria:

- Prior adalimumab therapy.

- Diagnosis of other active skin diseases or skin infections (bacterial, fungal, or
viral) that may interfere with evaluation of skin or fingernail psoriasis.

- Recent infection requiring treatment.

- Significant medical events or conditions that may put patients at risk for
participation, including recent history of drug or alcohol abuse.

- Female subjects who are pregnant or breast-feeding or considering becoming pregnant
during the study.

- History of cancer, except successfully treated skin cancer.